Investigating the long-term stability of protein immunogen(s) for whole recombinant yeast-based vaccines
Abstract
Even today vaccine(s) remains a mainstay in combating infectious diseases. Many yeast-based vaccines are currently in different phases of clinical trials. Despite the encouraging results of whole recombinant yeast (WRY) and yeast display (YD), the systematic study assessing the long-term stability of protein antigen(s) in yeast cells is still missing. Therefore, in the present study, I investigate the stability of heterologous protein antigen in the cellular environment of S. cerevisiae through E. coli surface protein (major curlin or CsgA). Present biochemical data showed that the stationary phase yeast cells were able to keep the antigen stable for almost one year when stored at 2-8 {degrees}C and 23-25 {degrees}C. Further, iTRAQ based quantitative proteomics of yeast whole cell lysate showed that the level of heterologous fusion protein was low in cells stored at 23-25 {degrees}C compared to those at 2-8 {degrees}C. In the end, I also proposed a workable strategy to test integrity or completeness of heterologous protein in the yeast cell. I believe that the observations made in the present study will be really encouraging for those interested in the development of a whole recombinant yeast-based vaccine(s).
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 19
- FWCI
- 0.62
- Field percentile
- top 35%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Lyophilized yeast powder for adjuvant free thermostable vaccine delivery
Ravinder Kumar, Bhushan N. Kharbikar·Applied Microbiology and BiotechnologyPeer-reviewed·Apr 1, 2021
- Preliminary stability studies of a ss-SARS-CoV-2 virus-like particle vaccine
Melissa Anne Edeling, Linda Earnest, … Joseph Torresi·bioRxiv·Mar 12, 2026
- A genome wide antigen-antibody screen identifies a yeast-based therapeutic vaccine candidate for Chagas disease
Mira Loock, Lissa Cruz‐Saavedra, … Igor dos Santos Cestari·bioRxiv·Jun 13, 2026
- Impact of storage on the stability and the protective effect of extracellular vesicles released by Candida albicans
Leandro Honorato, Jhon Jhamilton Artunduaga Bonilla, … Leonardo Nimrichter·Applied and Environmental MicrobiologyPeer-reviewed·Nov 28, 2025
- Production of antigenically stable enterovirus A71 virus-like particles in Pichia pastoris as a vaccine candidate.
N. J. Kingston, J. S. Snowden, … N. J. Stonehouse·bioRxiv·Jan 30, 2023
- Production and characterisation of stabilised PV-3 virus-like particles using Pichia pastoris
L. Sherry, K. Grehan, … N. J. Stonehouse·bioRxiv·Sep 16, 2022